FIELD: medicine.
SUBSTANCE: present group of inventions relates to medicine, namely to therapy and neurology, and concerns the treatment of circadian rhythm disorders. To do this, tasimelteon is administered in an amount of 5 to 300 mg/day within the developed dose schedules.
EFFECT: this ensures restoration of the 24-hour daily cycle, including in completely blind patients.
18 cl, 17 dwg, 10 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF CIRCADIAN RHYTHM VIOLATIONS | 2013 |
|
RU2631602C2 |
| TREATMENT OF CIRCADIAN RHYTHM DISORDERS | 2013 |
|
RU2650647C2 |
| WAY TO IMPROVE SLEEP | 2020 |
|
RU2804441C2 |
| METHODS OF IMPROVING SLEEP AND PERFORMANCE AFTER SLEEP | 2019 |
|
RU2822076C2 |
| MELATONIN AGONIST THERAPY | 2007 |
|
RU2488392C2 |
| METHOD OF TREATMENT OF PATHOLOGICAL DEVIATIONS AT DIABETES MELLITUS OF TYPE-2 | 1992 |
|
RU2104698C1 |
| HYDROCORTISONE COMPOSITION WITH CONTROLLED RELEASE | 2013 |
|
RU2619869C2 |
| AGENT FOR TREATMENT OF DESYNCHRONIZATION TROUBLES, AND PHARMACEUTICAL COMPOSITION | 1994 |
|
RU2160101C2 |
| METHODS FOR TREATMENT OF DISORDERS OF CIRCADIAN SLEEP RHYTHM | 2017 |
|
RU2763493C2 |
| METHOD OF DETERMINING CHARACTERISTICS OF CIRCADIAN RHYTHM OF SUBJECT | 2011 |
|
RU2587926C2 |
